Study Title and Description
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Key Questions Addressed
|7||Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving a SVR in patients with HCV infection?|
|8||Key Question 8. What are the harms of currently recommended antiviral treatments?|
Primary Publication Information
|Title||Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.|
|Author||Poordad F., Felizarta F., Asatryan A., Sulkowski MS., Reindollar RW., Landis CS., Gordon SC., Flamm SL., Fried MW., Bernstein DE., Lin CW., Liu R., Lovell SS., Ng TI., Kort J., Mensa FJ.|
|Country||Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX.|
Pubmed ID: 28128852
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-9
Results & Comparisons
No Results found.